Pharmaceutical composition for preventing and treating diabetic retinopathy

A technology for diabetic retina and composition, which is applied in the field of pharmaceutical compositions for proliferative diabetic retinopathy, can solve the problems that experimental research has not been widely carried out and the understanding is limited.

Inactive Publication Date: 2020-10-09
SHANGHAI XINSHENGYUAN BIOLOGICAL MEDICAL +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with other complications of diabetes, experimental research on C-peptide and proliferative diabetic retinopathy has not been widely carried out, and the understanding is relatively limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and treating diabetic retinopathy
  • Pharmaceutical composition for preventing and treating diabetic retinopathy
  • Pharmaceutical composition for preventing and treating diabetic retinopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Example 1 VEGF ELISA of Rat Retinal Tissue and Measurement of Nitric Oxide NO Content in Eyeball Tissue

[0096] Materials: At the end of the twelfth week, 10 rats in each group were killed by dislocation of the neck, and the left and right eyeball tissues were removed. At the same time, blood samples were taken from the orbital vein after the left and right eyeball tissues were removed, and the eyeballs and blood samples were refrigerated according to the corresponding group number. The left and right eyeball tissues of each group of rats were dissected, and the retinal tissues were added to the pre-cooled homogenate medium, and the cells were broken to obtain tissue homogenate for detection of the expression level of VEGF in the retinal tissues. Blood samples were centrifuged to obtain serum for the determination of NO content.

[0097] Rat vascular endothelial growth factor (VEGF) ELISA kit was purchased from Shanghai Renjie Biotechnology Co., Ltd. Sensitivity: the d...

Embodiment 2

[0130] Example 2 Determination of Nitric Oxide NO Content in Eyeball Tissue

[0131] Determination method: microplate method

[0132] Kit: nitric oxide (NO) assay kit (Nanjing Jiancheng Institute of Bioengineering; specification: 96T; detection range: 0-600μmol / L; bottom detection line: 1.8μmol / L);

[0133] Instruments: 1. Spectrophotometer 2. Constant temperature water bath (incubation temperature is 37°C) 3. Vortex mixer 4. Desktop centrifuge 5. Micropipette

[0134] Operation process: operate according to the instruction manual.

[0135] Statistical analysis: The results of each group that conformed to the normal distribution were expressed as mean ± standard deviation. The comparison between multiple groups was performed by one-way analysis of variance, and the pairwise comparison between the means of each group was performed by the SNK-q test. The results are shown in the table.

[0136]The difference among the 9 groups was statistically significant (F=19.87, P0.05); t...

Embodiment 3

[0147] Example 3 Evans blue (evans blue) method to measure the permeability of the blood-retinal barrier

[0148] Material collection: The remaining 10 rats in each group were taken to detect the EB value.

[0149] Reagent: Evans Blue (Company: Beijing Jinming Biotechnology Co., Ltd.; serial number: E80004; Dye content: ≥85%)

[0150] Operation: Operate according to the instructions of the reagents.

[0151] Statistical analysis: The results of each group that conformed to the normal distribution were expressed as mean ± standard deviation. The comparison between multiple groups was performed by one-way analysis of variance, and the pairwise comparison between the means of each group was performed by the SNK-q test. The results are shown in the table.

[0152] The difference among the 9 groups was statistically significant (F=194.84, P0.05); There were statistically significant differences among the remaining groups (P<0.05).

[0153] The average content of Evans blue EB l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for preventing and treating diabetic retinopathy, in particular to a pharmaceutical composition for preventing and treating diabetic retinopathy ina proliferation period, and the pharmaceutical composition can improve high expression of retinal VEGF, inhibit NO excessive synthesis and recover a blood-retinal barrier function. Experimental results show thatthe recombinant human proinsulin C peptide and the recombinant human plasminogen K5 can play a synergistic role; the synergistic treatment effect of the recombinant human proinsulin C peptide and the recombinant human plasminogen K5 is obviously superior to that of single use of the recombinant human proinsulin C peptide and the recombinant human plasminogen K5, i.e., the synergistic treatment effect of the recombinant human proinsulin C peptide and the recombinant human plasminogen K5 is obviously superior to that of simple addition of the recombinant human proinsulin C peptide and the recombinant human plasminogen K5. In addition, the pharmaceutical composition provided by the invention also has the advantages of good curative effect and low side effect.

Description

technical field [0001] The invention relates to the field of medicines, in particular, the invention relates to a pharmaceutical composition for preventing and treating diabetic retinopathy, especially a pharmaceutical composition for proliferative diabetic retinopathy. Background technique [0002] Diabetic retinopathy (diabetic retinopathy, DR) is one of its serious complications and one of the main blinding eye diseases. Its incidence is related to the duration of diabetes, age of onset, blood pressure and blood sugar control and other factors. Generally speaking, the incidence of DR is 38-39% for those with diabetes duration less than 5 years, and 69-90% for those with more than 10 years. DR is caused by long-term chronic hyperglycemia, retinal vascular self-regulation disorder, abnormal blood rheology, and blood-retinal barrier damage. The basic pathological manifestations of fundus lesions in DR are: (1) hyperpermeability of blood vessels; (2) occlusion of blood vess...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/49A61P3/10A61P9/10A61P27/02A23L33/18A23L33/10A61K38/28
CPCA23V2002/00A61K38/28A61K38/49A23L33/10A23L33/18A61P3/10A61P9/10A61P27/02A61K2300/00A23V2200/328
Inventor 贾伟平李校堃程萍倪晶
Owner SHANGHAI XINSHENGYUAN BIOLOGICAL MEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap